 CAMBRIDGE, Mass. BEIJING--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today presented results from the interim analysis of the Phase 3 ALPINE trial comparing its BTK inhibitor BRUKINSA zanubrutinib to ibrutinib in adult patients with relapsed or refractory RR chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL, including superiority in the primary e 